Search company, investor...

Founded Year

2017

Stage

Reverse Merger | IPO

Total Raised

$93.42M

About Oculis

Oculis develops topical treatments. The treatments are based on a Solubilizing Nanoparticle (SNP) technology that helps to formulate drugs as eye drops and their bioavailability in the eye tissues including both the front and the back of the eye. The company provides clients with technological advancement in ocular drug delivery. Oculis was founded in 2017 and is based in Lausanne, Switzerland.

Headquarters Location

EPFL Innovation Park Building D

Lausanne, 1015,

Switzerland

+41 21 711 3970

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Oculis Patents

Oculis has filed 12 patents.

The 3 most popular patent topics include:

  • Colloidal chemistry
  • Dosage forms
  • Drug delivery devices
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/28/2021

11/8/2022

Drug delivery devices, Dosage forms, Pharmacokinetics, Diseases of the eye and adnexa, Ophthalmology

Grant

Application Date

9/28/2021

Grant Date

11/8/2022

Title

Related Topics

Drug delivery devices, Dosage forms, Pharmacokinetics, Diseases of the eye and adnexa, Ophthalmology

Status

Grant

Latest Oculis News

Sanofi alum Sibold named CEO at Madrigal

Sep 12, 2023

Sanofi alum Sibold named CEO at Madrigal Plus: Fenimore to succeed Landry as Regeneron CFO and updates from SpringWorks, SalioGen, Oxular, Solu, Flagship, Oculis By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst September 11, 2023 11:06 PM UTC Bill Sibold succeeded Paul Friedman as CEO of Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL), which is developing therapies for non-alcoholic steatohepatitis. Sibold was most recently EVP, specialty care and president of the North America division at Sanofi (Euronext:SAN; NASDAQ:SNY), where he held roles for almost 12 years. Friedman, who became CEO in 2016, will continue as a board member; Sibold will also join Madrigal’s board. Robert Landry will retire as EVP, finance and CFO of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in February 2024, after a decade at the company. Landry will be succeeded by SVP, Head of Accounting and Controller Christopher Fenimore, who joined Regeneron in 2003 as VP of financial planning and analysis. The company also announced that Marc Tessier-Lavigne retired as a board member on Sept.1, a day after  he stepped down as Stanford's president. ... BCIQ Company Profiles

Oculis Frequently Asked Questions (FAQ)

  • When was Oculis founded?

    Oculis was founded in 2017.

  • Where is Oculis's headquarters?

    Oculis's headquarters is located at EPFL Innovation Park, Lausanne.

  • What is Oculis's latest funding round?

    Oculis's latest funding round is Reverse Merger.

  • How much did Oculis raise?

    Oculis raised a total of $93.42M.

  • Who are the investors of Oculis?

    Investors of Oculis include European Biotech Acquisition Corp., Brunnur Ventures, Silfurberg, Novartis Venture Funds, Bay City Capital and 12 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.